Abstracts tagged "pregnancy"

Abstract Number: 2632 • ACR Convergence 2025
Maternal vascular malperfusion: association with adverse perinatal outcomes in lupus pregnancies
ANA JIMENA LOPEZ DIAZ¹, MARIA DEL CARMEN ZAMORA MEDINA², Mario Isaac Lumbreras Márquez¹, Diana Yazmin Copado mendoza¹, Oralia Alejandra Orozco Guillén¹, Maria José rodríguez Sibaja¹, Martha Leticia Palafox Vargas¹ and Sandra Acevedo gallegos¹, ¹Instituto Nacional de Perinatología, Mexico City, Distrito Federal, Mexico, ²Instituto Nacional de Perinatologia, Mexico City, Distrito Federal, Mexico
Background/Purpose: Systemic lupus erythematosus (SLE) is associated with increased risk of adverse perinatal outcomes (APOs), including preeclampsia, preterm birth, fetal growth restriction, and stillbirth. Placental…
Abstract Number: 2218 • ACR Convergence 2025
Pregnancy Outcomes and Placental Findings in Women with IgA Vasculitis: A Case-Control Study
Edgar Iván Mendoza Ríos, María Del Carmen Zamora Medina, Mario Isaac Lumbreras Márquez, Diana Yazmin Copado mendoza, Oralia Alejandra Orozco Guillén, Maria José rodríguez Sibaja, Martha Leticia Palafox Vargas and Sandra Acevedo gallegos, Instituto Nacional de Perinatología, Mexico City, Distrito Federal, Mexico
Background/Purpose: IgA vasculitis (IgA-V) is a systemic vasculitis involving small vessels, most frequently affecting children. There is few information about pregnancy outcomes in women with…
Abstract Number: 2198 • ACR Convergence 2025
Sociocultural Influences on Pregnancy Planning for Individuals Diagnosed with SLE in an Urban Hispanic Population: A Qualitative Study with Considerations for a Holistic Approach
Andrew Ramirez¹, Alexa Montes de Oca¹, Martha Delgado¹, Mellissa withers¹ and Leanna Wise², ¹University of Southern California, Los Angeles, ²LAGMC/Keck Medicine of USC, Los Angeles
Background/Purpose: As systemic lupus erythematosus (SLE) often affects women of child-bearing age, understanding how this population makes reproductive health decisions is critical for well-rounded healthcare.…
Abstract Number: 0213 • ACR Convergence 2025
Development of a Predictive Tool for Obstetric Risk Stratification in Autoimmune Rheumatic Diseases: A Meta-Analysis-Based Model
Noe Macias-Segura¹, Rodolfo Martinez-Canales¹, Braulio R. Avalos-Garcia², Andres M. Ortiz-Rios², Eva Abigaid Galindo-Calvillo², Mario Cesar Salinas-Carmona¹, Lorena Perez-Barbosa², Dionicio A. Galarza-Delgado³ and Cassandra Michele Skinner-Taylor², ¹Immunology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, ²Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, ³Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico
Background/Purpose: Autoimmune rheumatic diseases (ARDs) such as systemic lupus erythematosus (SLE), antiphospholipid syndrome (APS), rheumatoid arthritis (RA), and Sjögren's syndrome significantly increase the risk of…
Abstract Number: 2631 • ACR Convergence 2025
Dapirolizumab Pegol, a Novel CD40L Inhibitor, Showed No Adverse Outcomes in an In Vivo Non-Human Primate Reprotoxicity Study and Displayed Minimal to No Human Placental Transfer in an Ex Vivo Study
Lewis Renshall¹, Birgit Hirschmugl², Bernd Potthoff³, Emmanuel Goursaud³, Pierre Bonnaillie³, Sarah Kettell³, Veerle Snoeck³, Emma Smith⁴, Farnaz Fallah-Arani⁴, Anthony Shock⁴, Alison Wolfreys⁴, Christian Wadsack² and Paul Brownbill¹, ¹Maternal and Fetal Health Research Centre, University of Manchester, Manchester, United Kingdom, ²Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria, ³UCB, Braine-l’Alleud, Belgium, ⁴UCB, Slough, United Kingdom
Background/Purpose: Dapirolizumab pegol (DZP) is a novel CD40L inhibitor with broad modulatory effects on SLE immunopathology;1,2 it consists of a polyethylene glycol (PEG)-conjugated antigen-binding fragment…
Abstract Number: 2216 • ACR Convergence 2025
Expanding Reproductive Health Assessments in Rheumatic Diseases: A Comparative Analysis of Demographic and Disease-Specific Factors
Krista Topalsky¹, Chelsea Guan², Lindsay Frumker³, Dana Nachawati², Areeb Tiwana⁴, Meghan Gump², Omer Pamuk⁵ and Marina Magrey⁶, ¹University Hospitals, Shaker Heights, OH, ²University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH, ³University hospitals Cleveland medical center, Highland Heights, OH, ⁴Canton Medical Education Foundation, Canton, OH, ⁵University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH, ⁶Case Western Reserve University School of Medicine/University Hospitals Cleveland, Richfield, OH
Background/Purpose: Building on our 2024 ACR study (Topalsky et al.) that described broad knowledge gaps and interest in reproductive health education among women with rheumatic…
Abstract Number: 2197 • ACR Convergence 2025
Mechanisms of Fetal Growth Restriction in Rheumatologic Autoimmune Diseases: Insights into Placental Pathology and Immune Dysregulation
Larabe Farrukh¹, Ananya Venkatesh², Mana Parast² and Chelsey Smith³, ¹University of California San Diego, San Diego, CA, ²University of California San Diego, San Diego, ³University of California San Diego, LA JOLLA, CA
Background/Purpose: Fetal growth restriction (FGR) significantly contributes to adverse pregnancy outcomes (APOs) in women with rheumatologic diseases. Understanding the immunopathologic mechanisms underlying FGR is critical…
Abstract Number: 0212 • ACR Convergence 2025
Biomarker-Guided Therapeutic Calculator for Personalized Management in Pregnant Patients with Autoimmune Rheumatic Diseases
Noe Macias-Segura¹, Rodolfo Martinez-Canales¹, Andres M. Ortiz-Rios², Braulio R. Avalos-Garcia², Eva Abigaid Galindo-Calvillo², Mario Cesar Salinas-Carmona¹, Lorena Perez-Barbosa², Dionicio A. Galarza-Delgado³ and Cassandra Michele Skinner-Taylor², ¹Immunology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, ²Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, ³Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico
Background/Purpose: Therapeutic decisions during pregnancy in women with autoimmune rheumatic diseases (ARDs) such as SLE, APS, RA, and Sjögren’s syndrome require a personalized approach due…
Abstract Number: 2630 • ACR Convergence 2025
The Absence of DORIS Remission Is Associated with Greater Risk of Preterm Birth and Preeclampsia in SLE Pregnancies
Camila Hernández-Blanco¹, Philip Carlucci², Peter Izmirly³, Jessica Dai⁴, Mala Masson⁵, Michael Belmont¹, Amit Saxena⁶, Jane Salmon⁷, Justin Brandt¹ and Jill Buyon⁸, ¹NYU Langone Health, New York, NY, ²New York University School of Medicine, New York, NY, ³New York University Grossman School of Medicine, New York, NY, ⁴New York University Grossman School of Medicine, Tenafly, NJ, ⁵NYU Langone Medical Center- Division of Rheumatology, New York, NY, ⁶Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine, New York, NY, ⁷Hospital for Special Surgery, New York, NY, ⁸NYU Grossman School of Medicine, New York, NY
Background/Purpose: Systemic Lupus Erythematosus (SLE) primarily affects females of childbearing age and increases the risk of adverse pregnancy outcomes (APOs), particularly in non-White individuals and…
Abstract Number: 2215 • ACR Convergence 2025
Placenta Abnormalities in Systemic Lupus Erythematosus: Novel Marker of Adverse Pregnancy Outcomes
Kaitlin Nuechterlein¹, Karl Grenier¹, Luisa Ciofani², Kalliopi Panaritis², Sasha Bernatsky² and Evelyne Vinet², ¹McGill University, Montreal, QC, Canada, ²Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Placenta-mediated adverse pregnancy outcomes (APO) are a huge concern in SLE. Recent efforts to understand APO include the establishment of the 2016 Amsterdam classification…
Abstract Number: 2196 • ACR Convergence 2025
Recognition and Treatment of Idiopathic Granulomatous Mastitis: A Case Series
Jenny Solomon¹, Julie Piccione¹, Julie Nusbaum², Steven Carsons³ and Gregg Blumberg¹, ¹NYU Langone Long Island, Mineola, ²NYU Langone Health, New York, NY, ³NYU Long Island School of Medicine, Mineola, NY
Background/Purpose: Idiopathic Granulomatous Mastitis (IGM) is a rare benign inflammatory condition of the breast usually affecting women of childbearing age with a history of breastfeeding.…
Abstract Number: 0159 • ACR Convergence 2025
Prenatal and Early-Life Environmental Exposures in Juvenile-Onset Systemic Autoimmune Rheumatic Diseases
Takuma Ohnishi¹, Megan Zhao¹, Min Shi², Adam Schiffenbauer³, Sharon Jackson³, Anna Jansen¹, Nastaran Bayat⁴, Payam Farhadi¹, Christine Parks², Clarice Weinberg², Frederick Miller⁵ and Lisa Rider⁶, ¹National Institutes of Health/National Institute of Environmental Health Sciences, Bethesda, MD, ²National Institutes of Health/National Institute of Environmental Health Sciences, Research Triangle Park, NC, ³National Institute of Health/National Institute of Dental and Craniofacial Research, Bethesda, MD, ⁴National Institutes of Health/National Institute of Environmental Health Sciences, Gaithersburg, MD, ⁵National Institutes of Health/National Institute of Environmental Health Sciences, Chapel Hill, NC, ⁶National Institute of Environmental Health Sciences/National Institutes of Health, Environmental Autoimmunity Group, Bethesda, MD
Background/Purpose: Systemic autoimmune rheumatic diseases (SARDs), including juvenile idiopathic arthritis (JIA), systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc), are characterized…
Abstract Number: 2629 • ACR Convergence 2025
Predictors of 30-day Readmissions in Pregnant Patients with Systemic Lupus Erythematosus: The Impact of Social Determinants of Health.
Sandhya Kannayiram¹, Yiyuan Wu², Lisa Sammaritano³, Michael Lockshin⁴, Rich Caruana⁵, Ware Branch⁶, Jane Salmon³ and Bella Mehta⁷, ¹Hospital for Special Surgery, Weill Cornell Medicine, New York, ²Weill Cornell Medicine, New York, NY, ³Hospital for Special Surgery, New York, NY, ⁴Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁵Microsoft, Redmond, WA, ⁶University of Utah Health Sciences Center, Salt Lake City, UT, ⁷Hospital for Special Surgery, Weill Cornell Medicine, Jersey City, NJ
Background/Purpose: Social Determinants of Health (SDOH) are increasingly recognized as significant contributors to adverse outcomes in pregnant patients with SLE. This study aims to evaluate…
Abstract Number: 2214 • ACR Convergence 2025
Hydroxychloroquine and Pregnancy Outcomes in Lupus: Results from a population-based cohort study
Sadaf Sediqi¹, leo lu², J. Antonio Aviña-Zubieta³ and Julia F Simard⁴, ¹Stanford University, Palo Alto, CA, ²Arthritis Research Canada, Vancouver, BC, Canada, ³University of British Columbia/Arthritis Research Canada, Vancouver, BC, Canada, ⁴Stanford Medicine, Stanford, CA
Background/Purpose: Systemic lupus erythematosus (SLE) can pose an increased risk of adverse pregnancy outcomes such as preeclampsia and preterm delivery. Hydroxychloroquine (HCQ), commonly used to…
Abstract Number: 1985 • ACR Convergence 2025
Identifying Gaps in Documented Contraception Counseling and Gynecology Referrals for Women on Teratogenic DMARDs: A Foundation for EMR-Based Quality Improvement
Rachel Galvao, Anokhi Saklecha, Julia Stevenson, Ritche Hao, Eugenia Chock and Abhijeet Danve, Yale University, New Haven, CT
Background/Purpose: Teratogenic medications are commonly prescribed to women of reproductive age who have rheumatic conditions. Counseling on teratogenicity and contraception is critical to reducing patients’…

1
2
3
…
22
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].